Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models

Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with poor survival. Cytoreduction in association with radiotherapy and temozolomide (TMZ) is the standard therapy, but response is heterogeneous and life expectancy is limited. The combined use of chemotherapeutic agents with d...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Valtorta, Silvia, Lo Dico, Alessia, Raccagni, Isabella, Gaglio, Daniela, Belloli, Sara, Politi, Letterio S, Martelli, Cristina, Diceglie, Cecilia, Bonanomi, Marcella, Ercoli, Giulia, Vaira, Valentina, Ottobrini, Luisa, Moresco, Rosa Maria
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5762574/
https://ncbi.nlm.nih.gov/pubmed/29348889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23028
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items